KYTHERA Biopharmaceuticals (FRA:KYT) Accounts Receivable : €0.00 Mil (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. KYTHERA Biopharmaceuticals's accounts receivables for the quarter that ended in Jun. 2015 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. KYTHERA Biopharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2015 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. KYTHERA Biopharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Jun. 2015 was €4.68.

KYTHERA Biopharmaceuticals Accounts Receivable Historical Data

The historical data trend for KYTHERA Biopharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KYTHERA Biopharmaceuticals Accounts Receivable Chart

KYTHERA Biopharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Accounts Receivable

KYTHERA Biopharmaceuticals Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15
Accounts Receivable	Get a 7-Day Free Trial														-	-	-	-	-

KYTHERA Biopharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

KYTHERA Biopharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

KYTHERA Biopharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2015 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.257	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), KYTHERA Biopharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

KYTHERA Biopharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2015 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(164.705	+	0.75 * 0	+	0.5 * 3.572	-	43.621
-	0	-	0)	/	26.249
=	4.68

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

KYTHERA Biopharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » Accounts Receivable

Traded in Other Exchanges

N/A

Address

Website

http://www.kytherabiopharma.com

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines